Studies have also shown a significant reduction in systolic and diastolic blood pressures after Zinc supplementation .
This first comprehensive systematic review and meta- analysis on the effects of Zinc supplementation in patients with diabetes demonstrates that Zinc supplementation  has beneficial effects on glycaemic control and promotes healthy lipid parameters .
The number of people with diabetes and pre-diabetes are exponentially increasing .
Studies on humans have shown the beneficial effects of Zinc supplementation in patients with diabetes .
The present study aims to systematic ally evaluate the literature and meta-analyze the effects of Zinc supplementation on diabetes .
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
OBJECTIVE This study evaluated the effects of exenatide , a novel incretin mimetic , in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy .  RESEARCH DESIGN AND METHODS A 30-week , double-blind , placebo-controlled study was performed in 733 subjects ( aged 55 + /- 10 years , BMI 33.6 + /- 5.7 kg/m(2 ) , A1C 8.5 + /- 1.0 % ; means + /- SD ) r and omized to 5 microg subcutaneous exenatide b.i.d . ( arms A and B ) or placebo  for 4 weeks . Thereafter , arm A remained at 5 microg b.i.d . and arm B escalated to 10 microg b.i.d . Subjects continued taking their dose of metformin and were r and omized to either maximally effective ( MAX ) or minimum recommended ( MIN ) doses of sulfonylurea . RESULTS Week 30 A1C changes from baseline ( + /-SE ) were -0.8 + /- 0.1 % ( 10 microg ) , -0.6 + /- 0.1 % ( 5 microg ) , and + 0.2 + /- 0.1 % ( placebo ; adjusted P < 0.0001 vs. placebo ) , yielding placebo-adjusted reductions of -1.0 % ( 10 microg ) and -0.8 % ( 5 microg ) . In the evaluable population , exenatide-treated subjects were more likely to achieve A1C < or = 7 % than placebo-treated subjects ( 34 % [ 10 microg ] , 27 % [ 5 microg ] , and 9 % [ placebo ] ; P < 0.0001 ) . Both exenatide arms demonstrated significant weight loss ( -1.6 + /- 0.2 kg from baseline each exenatide arm , -0.9 + /- 0.2 kg placebo ; P < or = 0.01 vs. placebo ) . Mild or moderate nausea was the most frequent adverse event . The incidence of mild/moderate hypoglycemia was 28 % ( 10 microg ) , 19 % ( 5 microg ) , and 13 % ( placebo ) and appeared lower with MIN than with MAX sulfonylurea treatment . CONCLUSIONS Exenatide significantly reduced A1C in patients with type 2 diabetes unable to achieve adequate glycemic control with maximally effective doses of combined metformin-sulfonylurea therapy . This improvement in glycemic control was associated with no weight gain and was generally well tolerated
Studies have also shown a significant reduction in systolic and diastolic blood pressures after Zinc supplementation .
This first comprehensive systematic review and meta- analysis on the effects of Zinc supplementation in patients with diabetes demonstrates that Zinc supplementation  has beneficial effects on glycaemic control and promotes healthy lipid parameters .
The number of people with diabetes and pre-diabetes are exponentially increasing .
Studies on humans have shown the beneficial effects of Zinc supplementation in patients with diabetes .
The present study aims to systematic ally evaluate the literature and meta-analyze the effects of Zinc supplementation on diabetes .